DUBLIN and MYSTIC, Conn., March 16, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN), a clinical-stage biopharmaceutical company focused on
cardiovascular disease, today reported financial results for the
fiscal year and fourth quarter ended December 31, 2010. The Company
also provided an update on its progress with the Phase 3
development program of its lead product candidate, AMR101 for the
treatment of elevated triglyceride levels, which are associated
with the increased risk of developing cardiac disease as well as
being a component of certain other metabolic disorders, such as
diabetes and obesity.
As reported by Amarin, key accomplishments since the Company’s
last quarterly financial report of September 30, 2010, include:
Primary endpoints met in Phase 3 MARINE trial with AMR101 at both
4g and 2g doses Strengthened balance sheet with additional $98.7M
cash Completed last patient visit for the Phase 3 ANCHOR trial
Strengthened management team with focus on commercial
–readiness of AMR101 through the addition of an accomplished
Chief Commercial Officer On-track with the existing MARINE trial
data for a New Drug Application (NDA) submission for AMR101 in Q3,
2011
“2010 was a year of great progress for Amarin. We accomplished
our goal of advancing AMR101 toward commercial status with the
release of positive MARINE trial results in the last quarter,”
stated Joseph Zakrzewski, Executive Chairman and Chief Executive
Officer of Amarin. “Among prescription Omega-3 based drugs,
AMR101 has the potential to be best-in-class for treating patients
with very high triglycerides and the first-in-class for treating
patients with high triglycerides with mixed dyslipidemia. Our focus
is to become the leader in the market for triglyceride-lowering
drugs by providing clinicians and patients a new generation of
prescrip
‘/>”/>
